Coronavirus - Drug Discovery and Therapeutic Options
Abdul Samad Tayyab, Maria Qurban, Maryam Mazhar, Zaid Tayyab, Mariam Tahir, Zain Tayyab
Journal of Pharmaceutical Research International · pp. 154–158 · Published 15 Nov 2021
10.9734/jpri/2021/v33i50A33391Abstract
COVID-19 is basically a medium size RNA virus and the nucleic acid is about 30 kb long, positive in sense, single stranded and polyadenylated. The RNA which is found in this virus is the largest known RNA and codes for a large polyprotein. In addition, coronaviruses are capable of genetic recombination if 2 viruses infect the same cell at the same time. SARS-CoV emerged first in southern China and rapidly spread around the globe in 2002–2003. In November 2002, an unusual epidemic of atypical pneumonia with a high rate of nosocomial transmission to health-care workers occurred in Foshan, Guangdong, China. In March 2003, a novel CoV was confirmed to be the causative agent for SARS, and was thus named SARS-CoV. Despite the report of a large number of virus-based and host-based treatment options with potent in vitro activities for SARS and MERS, only a few are likely to fulfil their potential in the clinical setting in the foreseeable future. Most drugs have one or more major limitations that prevent them from proceeding beyond the in vitro stage. First, many drugs have high EC50/Cmax ratios at clinically relevant dosages.
Cited by 7
D. Achola · Asian Research Journal of Mathematics · 2022
F. Khan, Tauseef Ahmad, M. Gulistan · Human Vaccines & Immunotherapeutics · 2021
Vergílio Pereira Carvalho, Nívia Cristina Ferreira, Adrialdo Jose Santos · Revista UNINGÁ · 2020
M. Nasrollahzadeh, Mohaddeseh Sajjadi, G. Soufi · Nanomaterials · 2020
Aleksandra Łoczechin, K. Séron, A. Barras · ACS Applied Materials and Interfaces · 2019
Atul Desai, K. Desai, Hemshree A. Desai · 2022
Ieppala Sripriya, A. Reddy, N. Shalini · 2020
Related research
- The Nature and Complications of Acute Traumatic Cervical Spinal Cord Injury in a University Hospital in Nigeria — shares topic coverage
- Risk Factors Assessment of Zoonotic Anthrax among the People at Risk (PAR) in Selected Areas of Bangladesh — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Systematic Review of Visceral Leishmaniasis in Central Africa — shares topic coverage
- Administration of High-Risk Medication: A Hospital Based Prospective Study — shares topic coverage
Article metrics
Real usage data collected on this platform.
1
Page views
0
PDF downloads
0
Outbound clicks
7
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.